TYRA · Tyra Biosciences, Inc.
$20.42
-0.15% last session
End-of-day data · close of 2026-10-26
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-7.4
Dividend yield
0.0%
Beta
0.75
Avg volume
1M
Employees
0K
Daily Change %
-0.15%
5 Days Change
-2.16%
10 Days Change
10.26%
30 Days Change
-6.16%
60 Days Change
-18.12%
Month to Day Change
-2.81%
Year to Day Change
-22.33%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TYRA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-22
Latest call per bank · past 12 months
Bank of America
Buy$42.00
+105.7% vs priceJefferies
Buy$43.00
+110.6% vs priceBarclays
Overweight$59.00
+188.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-22 | Oppenheimer | Reiterates | Outperform | $50.00 → $40.00 |
| 2026-09-22 | HC Wainwright & Co. | Maintains | Buy | $30.00 → $29.00 |
| 2026-09-10 | Wedbush | Reiterates | Outperform | $53.00 |
| 2026-09-10 | HC Wainwright & Co. | Maintains | Buy | $45.00 → $30.00 |
| 2026-09-04 | HC Wainwright & Co. | Reiterates | Buy | $45.00 |
| 2026-06-17 | Jones Trading | Initiates | Buy | $0.00 → $56.00 |
| 2026-06-10 | Bank of America | Maintains | Buy | $37.00 → $42.00 |
| 2026-05-19 | Wolfe Research | Initiates | Peer Perform | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 45 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 11.4% below the 50-day MA ($23.05).
- bearish: Price vs 200-day MA: Trading 32.0% below the 200-day MA ($30.03).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.33) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($14.23) and high ($39.61).
TYRA Price Chart
Loading chart for TYRA…
Fundamentals
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.